🔮 Better than the Oracle? Our Fair Value found this +42% bagger 5 months before Buffett bought itRead More

BRIEF-Cynapsus announces positive phase 3 results for Parkinson's drug

Published 2016-07-18, 04:33 p/m
© Reuters.  BRIEF-Cynapsus announces positive phase 3 results for Parkinson's drug
CTH
-

July 18 (Reuters) - Cynapsus Therapeutics Inc CTH.TO

* Top-Line CTH-300 results expected in late Q3 or early Q4

* New drug application for CTH-300 and CTH-301 with FDA expected to be submitted in first half of 2017.

* Cynapsus Therapeutics announces positive phase 3 dose titration phase results with APL-130277 for the treatment of off episodes in patients with Parkinson's disease

* APL-130277 was well tolerated Source text for Eikon: ID:nGNXMXVEGa Further company coverage: CTH.TO

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.